Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Cadila"

149 News Found

Zydus Cadila receives final approval for Apremilast
Drug Approval | September 24, 2021

Zydus Cadila receives final approval for Apremilast

Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy


Zydus Cadila receives final nod for anti-depressant
Drug Approval | September 18, 2021

Zydus Cadila receives final nod for anti-depressant

The medicine helps restore the balance of certain natural substances (serotonin) in the brain


Zydus Cadila seeks approval for a two-dose ZyCoV-D Covid-19 vaccine
News | September 13, 2021

Zydus Cadila seeks approval for a two-dose ZyCoV-D Covid-19 vaccine

The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.


Zydus Cadila gets US FDA approval for antidepressant tablets
Drug Approval | September 09, 2021

Zydus Cadila gets US FDA approval for antidepressant tablets

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.


Zydus Cadila’s Sitagliptin base tablets receive tentative approval from US FDA
Drug Approval | September 06, 2021

Zydus Cadila’s Sitagliptin base tablets receive tentative approval from US FDA

Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)


Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine
Biotech | August 20, 2021

Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine

This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC


Zydus Cadila receives tentative approval for cancer drug
News | August 17, 2021

Zydus Cadila receives tentative approval for cancer drug

Lenalidomide is used to treat cancer and also some anaemia disorders


Zydus Cadila receives final approval for Mesalamine extended-release capsules
Drug Approval | August 16, 2021

Zydus Cadila receives final approval for Mesalamine extended-release capsules

The group has a total of 320 ANDA approvals


Cadila Healthcare net profit at Rs 587.2 cr in Q1FY22
News | August 11, 2021

Cadila Healthcare net profit at Rs 587.2 cr in Q1FY22

The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine


Zydus Cadila receives approval from USFDA for Fulvestrant Injection
News | July 31, 2021

Zydus Cadila receives approval from USFDA for Fulvestrant Injection

The group now has 320 approvals and has so far filed over 400 ANDAs